Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02184442 · ClinicalTrials.gov registry record · NA
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B
A NA study, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- NA
- Development phase
- 560
- Enrollment target
NCT02184442 is a NA study that has completed, run by Edwards Lifesciences. The registered enrollment target is 560 participants.
The verdict
NCT02184442, a NA study, has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 560 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of the SAPIEN XT™ THV with the associated delivery system for inoperable patients with severe symptomatic native aortic stenosis.
Interventions
- DEVICE TAVR Implantation with SAPIEN XT
- DEVICE TAVR Implantation with SAPIEN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2011-03-09 |
| Est. Completion | 2017-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02184442
The ClinicalTrials.gov registry entry for NCT02184442 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAVR Implantation with SAPIEN XT is the first listed.
NCT02184442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02184442 about?
NCT02184442 is a clinical study titled "The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B". The purpose of this study is to determine the safety and effectiveness of the SAPIEN XT™ THV with the associated delivery system for inoperable patients with severe symptomatic native aortic stenosis.
What is the current status of trial NCT02184442?
This trial is currently completed. It is a NA study. The enrollment target is 560 participants. The study started on 2011-03-09. Estimated completion is 2017-05-30.
What interventions are being tested in trial NCT02184442?
The interventions under investigation include: TAVR Implantation with SAPIEN XT (DEVICE), TAVR Implantation with SAPIEN (DEVICE).
Who is sponsoring clinical trial NCT02184442?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.